Single-session treatment of benign thyroid nodules with radiofrequency ablation: Results at 6 months in 24 patients.

Autor: Familiar Casado C; Servicio de Endocrinología y Nutrición, Hospital Universitario Clínico San Carlos, Madrid, España. Electronic address: cristinafamiliarcasado@gmail.com., Merino Menendez S; Servicio de Radiodiagnóstico, Hospital Universitario Clínico San Carlos, Madrid, España., Ganado Diaz T; Servicio de Radiodiagnóstico, Hospital Universitario Clínico San Carlos, Madrid, España., Pallarés Gasulla R; Servicio de Endocrinología y Nutrición, Hospital Universitario Clínico San Carlos, Madrid, España., Pazos Guerra M; Servicio de Endocrinología y Nutrición, Hospital Universitario Clínico San Carlos, Madrid, España., Marcuello Foncillas C; Servicio de Endocrinología y Nutrición, Hospital Universitario Clínico San Carlos, Madrid, España., Calle Pascual A; Servicio de Endocrinología y Nutrición, Hospital Universitario Clínico San Carlos, Madrid, España.
Jazyk: English; Spanish; Castilian
Zdroj: Endocrinologia, diabetes y nutricion [Endocrinol Diabetes Nutr (Engl Ed)] 2020 Mar; Vol. 67 (3), pp. 164-171. Date of Electronic Publication: 2019 Aug 19.
DOI: 10.1016/j.endinu.2019.06.003
Abstrakt: Objective: To evaluate the efficacy and safety of one single-session of radiofrequency ablation (RFA) performed in thyroid benign and predominantly solid nodules.
Patients and Method: Unicentric retrospective study in usual clinical setting that included patients with solid and benign thyroid nodules treated with one single session of RFA and with folllow-up of at at least 6 months after the procedure. RFA was performed as an alternative to surgery in cases of pressure symptoms or nodular growth evidence. Patients were evaluated basally and at one, 3 and 6 months after RFA and also at 12 months if the follow-up was available. In each evaluation efficacy variables were recorded (percentual change from basal volume, percentage of nodules reaching a volume reduction above 50% from baseline, patients with disappearance of pressure symptoms and the possibility of antithyroid drug withdrawal) and safety variables were also registered including minor complications (pain needing analgesic drugs, hematoma) and major complications (voice changes, braquial plexus injury, nodule rupture and thyroid dysfunction).
Results: Twenty-four patients with a follow-up of at least 6 months after RFA were included, 16 of them with more than 12 months of follow-up. Mean nodule volume changed from 25.4±15.5ml basally to 10.7±9.9ml at month 6 (P<.05) and to 9.9±10,4ml at month 12 in 16 nodules. Six months after RFA mean volumetric reduction was 57.5±24% and 65% of the nodules reached a volume reduction above 50% from baseline. Median percentage of reduction at month 6 was 50.4±25.8% for nodules with a basal volume above 20ml (n=13) and 65.3±20.1% for nodules with a lower basal volume (n=11). Pressure symptoms reported in 12 patients disappeared in all cases. Antithyroid drugs could be stopped in 3 of 4 cases treated before RFA. A mild and transient pain responsive to conventional analgesic drugs was recorded in 9 patients during the 24h after the procedure and in 7 a small perithyroid and transient hematoma was observed in the 48 following hours. One major complication was described as a nodule rupture that recovered spontaneously. There were no changes in hormonal values in euthyroid cases.
Conclusion: A single session of RFA seems to be an effective and safe procedure in patients with solid thyroid nodules with pressure symptoms or relevant growth evidence. As an outpatient and scarless procedure with no need of general anaesthesia it could become an useful alternative to lobectomy when surgery is refused or in patients at high surgical risk.
(Copyright © 2019 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: